You may have heard people talk about “weight loss injections” or names like Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda.
So what are these medicines really, and what do they do inside your body?
GLP-1 medications are part of a growing group of treatments used for type 2 diabetes and, in some cases, obesity. They can lower blood sugar. They can also help many people eat less because they feel full sooner. But they are still prescription medicines, and they come with real risks and rules.
🔑 Key takeaways
|
What are GLP-1 medications?
Source: MedSupplyUS
GLP-1 stands for glucagon-like peptide-1. It is a hormone your body makes in the gut after you eat. GLP-1 receptor agonists are medicines that mimic that hormone’s effect. These drugs are also called GLP-1 receptor agonists, GLP-1 analogs, or incretin mimetics.
GLP-1 medicines are used for type 2 diabetes and sometimes obesity
GLP-1 receptor agonists are used to treat type 2 diabetes mellitus (T2DM) and, in some cases, obesity. They work as one of several medication options for these conditions, and they are often added when other steps do not reach blood sugar goals.
The American Diabetes Association (ADA) notes that metformin is still the preferred first-line treatment for type 2 diabetes. Still, the ADA suggests a GLP-1 medicine may be added when metformin cannot be used, when A1c stays high, or when a person has not reached their A1c target after about 3 months, especially when heart or kidney risks are present.
Common examples of GLP-1 drugs
Several medicines fall into this class. Examples include exenatide, liraglutide, dulaglutide, and semaglutide.
Some brand names have become well known:
- Ozempic and Wegovy contain the same active ingredient, semaglutide
- Mounjaro and Zepbound contain tirzepatide
- Saxenda contains liraglutide
GLP-1 drugs come in different “backbones”
GLP-1 receptor agonists can be grouped into two broad structural categories.
Human GLP-1 backbone:
- Dulaglutide
- Albiglutide (discontinued)
- Liraglutide
- Semaglutide
Exendin-4 backbone:
- Exenatide (two formulations)
- Lixisenatide (discontinued)
There are also newer approaches that target more than one hormone pathway.
Dual-acting medicines: GLP-1 plus another hormone
Tirzepatide is a GIP analog that activates both GLP-1 and GIP receptors. GIP stands for glucose-dependent insulinotropic polypeptide. It is another gut hormone that helps regulate blood sugar and appetite.
Why does that matter? When a medicine activates both pathways, it may lead to stronger effects for some people.
How do GLP-1 medications work in the body?
GLP-1 medicines work in several places at once: the pancreas, the stomach, the brain, and other organs. That is one reason they can affect both blood sugar and appetite.
The incretin effect and blood sugar control
GLP-1 and GIP are “incretin” hormones. After an oral glucose load, they help stimulate insulin secretion. This incretin effect becomes weaker or may disappear in type 2 diabetes, but higher, medication-level GLP-1 can help restore insulin release.
GLP-1 receptor agonists:
- Increase insulin secretion when blood sugar is high
- Reduce glucagon release from pancreatic alpha cells when blood sugar is high
This is important because glucagon is a hormone that raises blood sugar. Lower glucagon can help bring glucose down.
Slower stomach emptying and feeling full
GLP-1 medicines delay gastric emptying, so food moves more slowly from the stomach into the intestine. This helps reduce after-meal blood sugar spikes and can increase satiety.
Some research notes that delayed gastric emptying may be strongest early on, and overall gastric emptying may not stay affected in the same way over time
Even so, many people feel full sooner, and that can change eating patterns.
Have you ever felt like you got full faster than usual? That “full sooner” feeling is one reason these drugs can reduce food intake.
Appetite signals in the brain
GLP-1 also works in the central nervous system. It can increase satiety through direct action on the hypothalamus. A detailed review describes how GLP-1 receptor agonists can affect brain regions that control hunger, satiety, and reward.
GLP-1 receptor agonists can act in brainstem areas like the nucleus tractus solitarii and the area postrema. Signals then reach the hypothalamus, where appetite-suppressing pathways increase and appetite-stimulating pathways decrease.
The same review also describes effects in reward pathways, where dopamine signaling linked to food reward can drop. That can reduce cravings and help curb overeating.
Gut hormones, leptin, and hunger hormones
Appetite is not controlled by one signal. It is a network.
GLP-1 receptor agonists can influence gut hormones such as:
- Ghrelin (often called a hunger hormone)
- Peptide YY
- Cholecystokinin
The review also describes GLP-1 effects on leptin sensitivity. Leptin is a hormone made by fat tissue that tells the brain you have enough energy stored. When leptin resistance improves, the brain can respond better to fullness signals.
Do GLP-1 Medications Help With Diabetes and Weight Loss?
Yes, these medicines can help with both, but the goals and the way they are used can differ.
Benefits for type 2 diabetes
For type 2 diabetes, GLP-1 receptor agonists lower serum glucose and help manage metabolism. They also reduce A1c.
A meta-analysis found GLP-1 analogs reduced hemoglobin A1c by about 1% compared with control groups in people with type 2 diabetes.
The ADA guidelines also recommend GLP-1 receptor agonists to help reduce cardiovascular risk, with lower chances of cardiovascular events and hypoglycemia, plus potential help in slowing chronic kidney disease progression.
GLP-1 medicines with proven cardiovascular benefits include liraglutide, subcutaneous semaglutide, and dulaglutide.
Weight loss results seen in trials
GLP-1 receptor agonists can lead to weight loss. The same study above reports an average weight loss of 2.9 kg compared with placebo across studies, along with lower blood pressure and total cholesterol.
For obesity-focused trials, weight loss can be much larger.
According to a study, the SCALE trial found that after 56 weeks, mean weight loss was 8.4 kg in the liraglutide group versus 2.8 kg with placebo. The same trial reported 33.1% of participants in the liraglutide group lost more than 10% of their body weight, compared with 10.6% in the placebo group.
According to another study, the SCALE IBT trial found that intensive behavioral therapy plus liraglutide produced more weight loss than placebo, and more people reached 10% and 15% weight loss milestones.
Semaglutide trials also showed strong results:
- STEP 1 reported 14.9% weight loss with semaglutide versus 2.4% with placebo over 68 weeks.
- The same review describes STEP 3, where continued semaglutide reached up to 17.4% weight loss. When people switched to placebo, weight gain followed even with lifestyle support.
Tirzepatide showed large weight loss too:
- According to a study, SURMOUNT-1 found average weight loss of 15% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg. Placebo had 3.1% weight loss.
That is a wide range. So what changes outcomes? Dose, medicine type, and whether treatment continues all matter.
Who may be considered for weight management treatment?
For weight management, one guide describes typical use for people with:
- BMI of 30 or higher, or
- BMI of 27 or higher with a weight-related condition such as diabetes, obstructive sleep apnea, or high blood pressure
Another clinical perspective states weight loss medications are indicated when diet and activity changes have not been enough and BMI is 30 or higher, or 27 or higher with obesity-related comorbidities such as hypertension, hyperlipidemia, heart disease, or obstructive sleep apnea.
Broader effects and research findings on GLP-1 Drugs
GLP-1 drugs touch more than weight and blood sugar. Research and clinical guidance discuss heart, kidney, metabolism, medication forms, and future directions.
Heart and kidney outcomes
The 2023 ADA guidelines recommend GLP-1 receptor agonists for reducing cardiovascular risk, with lower risk of cardiovascular events and hypoglycemia, plus possible slowing of chronic kidney disease progression.
Clinical and mechanistic work also describes improvements in:
- left ventricular ejection fraction
- myocardial contractility
- coronary blood flow
- cardiac output
- endothelial function
Semaglutide also gained attention for cardiovascular risk reduction in a specific group.
According to a study, the SELECT trial showed a 20% reduction in cardiovascular events in patients with BMI 27 or higher who had preexisting cardiovascular disease and no diabetes.
Metabolic benefits beyond the scale
A detailed review explains that GLP-1 receptor agonists can improve lipid profiles, reduce triglycerides and LDL cholesterol, and reduce inflammation in fat tissue. It also discusses less ectopic fat deposition and possible fat redistribution patterns.
A primary care perspective also reports improvements in measures like waist circumference, blood pressure, fasting insulin, lipid levels, and A1c in people treated with tirzepatide in SURMOUNT-1, including many with prediabetes reaching normoglycemi. A post hoc analysis also described lower predicted atherosclerotic cardiovascular disease risk.
Different formulations and how they are taken
Most GLP-1 receptor agonists were injectable because oral bioavailability is poor. Many are given as subcutaneous injections:
- Liraglutide is often dosed daily.
- Dulaglutide and semaglutide are often dosed weekly.
- Exenatide can be dosed twice daily or weekly
An oral semaglutide formulation has also been FDA approved. According to a study, oral semaglutide was studied for cardiovascular outcomes in type 2 diabetes.
In real life, device type can shape experience too. Some medicines come as single-use pens, while others are multi-use pens that require new needles with each injection. Patient satisfaction may improve with weekly dosing compared with twice-daily regimens, although some concerns about weekly adherence have been raised.
Combination products and “next wave” therapies
Some therapies combine a GLP-1 analog with long-acting insulin in one injection. This approach can help cover fasting and post-meal blood sugar patterns and may reduce hypoglycemia risk compared with heavier reliance on bolus and basal insulin alone.
Research also continues on new agents:
- Taspoglutide trials were halted due to safety concerns
- Orforglipron, a nonpeptide oral GLP-1 receptor agonist, showed promising phase 2 results
Dual and triple co-agonists are another area of interest. According to the same study above, combinations that target GLP-1 alongside GIP and glucagon pathways may enhance weight loss and metabolic flexibility. This is an active research space.
What are some known concerns and effects of GLP-1 medications?
These medicines can help, but they can also cause side effects and require careful monitoring. Some risks are common and mild. Others are rare but serious. It is worth knowing what to watch for.
Common side effects, especially gut symptoms
The most common side effects are gastrointestinal:
- nausea
- vomiting
- diarrhea
- constipation
- dyspepsia
Most side effects are mild to moderate or short in duration, but nausea, vomiting, and diarrhea can sometimes cause severe dehydration that needs hospital care. Vomiting and diarrhea can lead to acute kidney injury due to volume contraction.
Side effects often show up after dose increases and can improve with time. That is why many protocols raise the dose step by step.
Gallbladder and biliary disease
A meta-analysis found an association between GLP-1 receptor agonist use and higher risk of gallbladder or biliary diseases, especially with higher doses and longer use.
Pancreatitis warning signs and uncertainty
Acute pancreatitis, including severe forms, has been reported in users of GLP-1 analogs, although a clear cause-and-effect link remains unknown. The regulator guidance also states pancreatitis has been reported, and it describes a key symptom: severe stomach pain that spreads to the back and does not go away.
Because of this concern, GLP-1 agonists should not be prescribed to patients with a history of pancreatitis and should be stopped if pancreatitis develops during treatment. A separate overdose case report describes liraglutide overdose-induced acute pancreatitis.
Thyroid-related boxed warning and who should avoid these drugs
Concerns about thyroid effects have been studied for years. Liraglutide stimulated calcitonin release and C-cell changes in rodent models. What this means for humans remains unclear, and more research is needed.
Because of this risk signal, GLP-1 agonists are not recommended for people with:
- a personal or family history of medullary thyroid cancer
- multiple endocrine neoplasia type 2A (MEN 2A)
- multiple endocrine neoplasia type 2B (MEN 2B)
Pregnancy, contraception, and breastfeeding rules
These medicines are not recommended in pregnancy, and some guidance stresses that people who can become pregnant should take steps to avoid pregnancy while using GLP-1 medicines. There is not enough safety data to know the risk to a baby, and animal studies raise concern.
The same guidance mentioned above lists wash-out times before trying to become pregnant:
| Medication | Wash-out time before trying to become pregnant |
| Semaglutide | At least 2 months |
| Tirzepatide | At least 1 month |
| Liraglutide | Stop just before trying to conceive (leaves the body quicker) |
Another key point: tirzepatide may reduce the effectiveness of oral contraceptives in people who are overweight or obese. The guidance recommends adding a barrier method for four weeks after starting and four weeks after dose increases, or switching to a non-oral method.
Hypoglycemia risk with certain combinations
On their own, GLP-1 receptor agonists have a low risk of minor hypoglycemia, and major episodes have not been described in some research summaries.
Still, risk can rise when these drugs are combined with sulfonylureas or insulin. That is why dose reductions may be needed, such as reducing insulin by around 25% depending on control.
Combination therapy of GLP-1 agonists and DPP-4 inhibitors is not recommended because improvement is small and hypoglycemia risk can increase.
Kidney, liver, and age considerations
GLP-1 analogs are mainly eliminated through the kidneys. Dosing changes are not needed for mild renal or hepatic impairment, but product guidance may suggest adjustments, especially in older adults.
Patients with severe renal dysfunction should not take GLP-1 agonists. Weekly exenatide should be avoided in moderate renal impairment, and dose escalations require care for twice-daily exenatide, especially in people aged 70 and older.
Drug interactions that need monitoring
Because GLP-1 medicines can delay gastric emptying, absorption of other drugs can change. Several interactions are highlighted, including:
- Warfarin, where monitoring INR may be needed
- Furosemide, with closer monitoring of electrolytes and kidney function
- Levothyroxine, with thyroid lab monitoring and dose adjustments as needed
- Oral hormonal contraceptives, where effectiveness may drop and barrier methods may be needed in certain cases
Surgery, anesthesia, and aspiration risk
Because GLP-1 medicines slow stomach emptying, some reports describe higher risk of regurgitation and aspiration during anesthesia. Guidance suggests temporary discontinuation before elective procedures, and it recommends following current fasting guidelines until stronger evidence exists.
Compounded semaglutide and dosing errors
The FDA issued a caution about compounded semaglutide, and reports describe adverse events tied to incorrect dosing and confusion with syringes and vial.
According to a study, a case series described administration errors from compounded semaglutide. In some cases, people took doses far higher than intended and had significant nausea, vomiting, and prolonged abdominal pain.
This is one reason regulated, prefilled pens and proper counseling matter so much.
Mental health signals and what reviews found
A clinical review notes an FDA alert from January 2024 about concerns related to suicidal thoughts and actions, with investigation ongoing. That same review reports the preliminary evaluation did not find evidence that these medicines cause suicidal thoughts or actions.
The UK regulator also reports that after a comprehensive safety review, available data does not support a causal link between GLP-1 medicines and depression, suicidal thoughts, or suicide, while monitoring continues .
| 🤔 What happens if someone takes too much? Research on overdoses is limited. Reports describe nausea, vomiting, diarrhea, belching, and abdominal pain, and some case reports describe supportive care as treatment. Serious complications like pancreatitis or hypoglycemia were not seen in some case studies, although the evidence base is still small. |
Final thoughts
If you are thinking about GLP-1 therapy, the safest next step is simple: have a real conversation with a qualified healthcare professional, review benefits and risks, and make a plan for monitoring.
Would you want a powerful medicine working in your body without a clear plan? Probably not.
FAQs on GLP-1 medications
Is GLP-1 the same as Ozempic?
No. GLP-1 is a natural hormone. Ozempic is a medicine that copies how GLP-1 works. Think of GLP-1 as the original and Ozempic as a lab-made version.
What’s the difference between Ozempic and Wegovy?
They use the same drug (semaglutide), but for different goals. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight loss and uses a higher dose.
Can you take GLP-1 medications if you don’t have diabetes?
Yes. Some GLP-1 drugs are FDA-approved for weight loss in people without diabetes, as long as they meet certain health criteria.
Which GLP-1 works best for weight loss?
Tirzepatide (Zepbound) leads to the most weight loss on average. Semaglutide (Wegovy) is also very effective. Results vary from person to person.
Are there GLP-1 supplements you can buy without a prescription?
No supplement works like prescription GLP-1 drugs. Some, like berberine, may help a little, but results are mild compared to prescription meds.
Is GLP-1 the same as metformin?
No. Metformin improves how your body uses insulin. GLP-1 meds work by slowing digestion, reducing appetite, and increasing insulin release after meals.
What are the most common side effects?
Most side effects affect the stomach. You may feel nausea, vomiting, diarrhea, constipation, or bloating. These often improve as your body adjusts.
What is “Ozempic face”?
“Ozempic face” comes from fast weight loss, not the drug itself. Losing fat quickly can make the face look thinner or saggy. Slower weight loss can help reduce this.
Who should not take GLP-1 medications?
You should avoid them if you have certain thyroid cancers, MEN 2, severe stomach emptying problems, or a history of pancreatitis. Always check with your doctor first.
Sources
Collins, L., & Costello, R. A. (2024). Glucagon-like peptide-1 receptor agonists. In StatPearls [Internet]. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK551568/
American Diabetes Association. (2019). Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2019. Diabetes Care, 42(Suppl. 1), S90–S102. https://doi.org/10.2337/dc19-S009
Mohr, K., & Butcher, C. (2024). Glucagon-like peptide-1 receptor agonists for weight loss: A primary care perspective. Missouri Medicine, 121(6), 489–494. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651266/
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025). Mechanisms of GLP-1 receptor agonist–induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. The American Journal of Medicine, 138(6), 934–940. Retrieved from https://www.amjmed.com/article/S0002-9343(25)00059-2/fulltext
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. The New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020). Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial. Obesity, 28(3), 529–536. https://doi.org/10.1002/oby.22726
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023). Semaglutide for the treatment of obesity. Trends in Cardiovascular Medicine, 33(3), 159–166. https://doi.org/10.1016/j.tcm.2021.12.008
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
American Diabetes Association. (2019). Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2019. Diabetes Care, 42(Suppl. 1), S90–S102. https://doi.org/10.2337/dc19-S009
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Griffin, R., Stefanski, A., & Garvey, W. T. (2024). Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes, Obesity and Metabolism, 26(1), 319–328. https://doi.org/10.1111/dom.15318
AlSaadoun, A. R., AlSaadoun, T. R., & Al Ghumlas, A. K. (2022). Liraglutide overdose-induced acute pancreatitis. Cureus, 14(1), e21616. https://doi.org/10.7759/cureus.21616
Knudsen, L. B., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., Jacobsen, S. D., Moses, A. C., Mølck, A.-M., Nielsen, H. S., Nowak, J., Solberg, H., Thi, T. D. L., Zdravkovic, M., & Moerch, U. (2010). Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology, 151(4), 1473–1486. https://doi.org/10.1210/en.2009-1272
Gulak, M. A., & Murphy, P. (2023). Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: A case report. Canadian Journal of Anesthesia, 70(8), 1397–1400. https://doi.org/10.1007/s12630-023-02521-3
Lambson, J. E., Flegal, S. C., & Johnson, A. R. (2023). Administration errors of compounded semaglutide reported to a poison control center: Case series. Journal of the American Pharmacists Association, 63(5), 1643–1645. https://doi.org/10.1016/j.japh.2023.06.017
Author Bio: Dr. Adrian Blackwell is the founder and CEO of PonteVita Rx, a telehealth practice dedicated to making medication access simpler, more affordable, and less stressful. Licensed to practice medicine in all 50 states and DC, Dr. Blackwell is board certified in obesity medicine and emergency medicine. He combines clinical expertise with personal experience navigating the healthcare system as a patient and parent to children with chronic illnesses. His mission: ensure everyone has access to their necessary medications without unnecessary barriers.
Medical Disclaimer: All the information here, on these videos, YouTube, social media, or in any other format, is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult your personal physician or other qualified health provider with any questions you may have regarding a medical condition. Never replace professional medical advice given to you personally or delay in seeking it because of something you have read or heard on this website. This information is not meant to diagnose, treat, or cure any medical condition. No patient-physician relationship is formed. If you’re my patient, please text me before you make any changes to your medication. If you believe you are having a medical emergency please call 911.